RNA technology

Advances in synthetic biology enable the production of nearly any targeted protein through mRNA-based vaccines and therapies. We have developed dedicated platforms allowing high-throughput screening and validation of therapeutic candidates like antigens and T cell or chimeric antigen receptors. What makes our approach unique is its adaptability. Each platform is designed to optimize RNA molecule development based on a specific application. We can fine-tune and optimize the design of therapeutic RNA molecules, ensuring the best possible outcome for each use. This flexibility paves the way for more efficient preclinical research and supports the development of next-generation RNA-based individualized therapies.